PTSD

A new study has challenged the commonly held belief that consciously suppressing negative thoughts is bad for our mental health, finding that people who did so had lower levels of post-traumatic stress and anxiety and less vivid intrusive thoughts.

Scientists have discovered that attention-deficit/hyperactivity disorder (ADHD), which is largely inherited, directly increases the risk of sufferers also developing major depression, post-traumatic stress, anorexia nervosa and attempting suicide.

In a world first, two illicit substances best known for their ‘recreational’ use have been given the tick of approval by Australian authorities to be prescribed for the treatment of post-traumatic stress disorder (PTSD) and drug-resistant depression.

A first-of-its-kind meta-analysis of 97 studies shows that physical activity can be as, or more effective in relieving symptoms of various mental disorders as traditional treatment, legitimizing exercise as more than just a complementary therapy.

When it comes to PTSD, much of the clinical research focuses on improving the condition rather than predicting it. However, a new study has uncovered a brain marker that seems to show who is more likely to develop PTSD when exposed to trauma.

When someone is suffering from post-traumatic stress disorder, psychiatrists will sometimes have them place themselves in stress-triggering environments. An experimental wearable system has now been shown to make such treatment much more effective.

Studies continue to illuminate the wide-ranging benefits of physical activity when it comes to brain health, and new research has shown how that might include treatment of post-traumatic stress disorder (PTSD).

Striking new research proposes taking a common anti-inflammatory drug soon after experiencing a traumatic event could help people forget upsetting memories and reduce their risk of developing post-traumatic stress disorder (PTSD).

A trial exploring MDMA-assisted therapy in a group setting is about to commence following the resolution of a clinical hold placed by the FDA that paused progress for several months. The trial's goal is to make MDMA-assisted therapy more cost-effective.

The first results from Phase 3 trials testing MDMA-assisted psychotherapy for PTSD have been announced. The promising data are the first Phase 3 results to be revealed for any psychedelic-based therapy paving the way for a landmark FDA approval in 2023.

Surfing the wave of new research into medical uses for psychedelic compounds, the Icahn School of Medicine at Mount Sinai has launched a dedicated psychedelic center focusing on the study of MDMA and psilocybin for PTSD and other stress-related conditions.

For the first time in decades, a pilot study has explored the effects of MDMA therapy in couples within the framework of a robust clinical trial. Following on from ongoing research into MDMA-assisted therapy for PTSD, the results are promising.